Apply for Hetlioz (Tasimelteon) Copay Assistance Now.

Hetlioz is a prescription medication for treating Non-24-Hour Sleep-Wake Disorder (Non-24) and sleep disturbances associated with Smith-Magenis Syndrome (SMS). Its active ingredient, tasimelteon, helps regulate the sleep-wake cycle by targeting melatonin receptors.

Learn more about Hetlioz here.

Tasimelteon is the active compound in Hetlioz. In this case, an active compound is essentially the main ingredient in the medication that helps patients achieve the desired effect.  It is a melatonin receptor agonist used to treat circadian rhythm (sleep) disorders.

The cost of Hetlioz will vary between patients as medical costs are directly affected by personal factors such as; type of insurance plan, locat and availability of a generic. Discounts, copay assistance programs, and insurance coverage may reduce the price.

This is where QuickRx can help. We work to connect patients who qualify with copay assistance. Click the button below to give us a call or fill out the form on this page to see if you qualify.
(917) 830-2525

Yes. QuickRx Specialty Pharmacy offers completely free enrollment support for Hetlioz copay assistance programs. We don’t charge application fees, service charges, or consultation fees—our mission is to help you access affordable treatment for Non-24-Hour Sleep-Wake Disorder.

Our free copay assistance services include complete application assistance for manufacturer copay cards and patient assistance programs, insurance benefit verification and coverage analysis, prior authorization coordination with your insurance company, continuous benefit monitoring to maintain your savings throughout treatment, appeals assistance if your application is initially denied, and home delivery coordination with specialty packaging for light-sensitive medications.

According to the Centers for Medicare & Medicaid Services, patients have the right to access financial assistance programs without pharmacy service fees. QuickRx adheres to all federal and state regulations regarding copay assistance enrollment.

Eligibility for Hetlioz copay assistance depends on your insurance type, medical diagnosis, and financial circumstances. The FDA approved Hetlioz specifically for Non-24-Hour Sleep-Wake Disorder, and most assistance programs require a valid diagnosis and prescription from a healthcare provider.

Commercially insured patients may qualify for manufacturer copay cards that dramatically reduce out-of-pocket costs, often to $0 per prescription. These programs typically have income restrictions and require active commercial insurance coverage. Medicare and Medicaid patients cannot use manufacturer copay cards due to federal Anti-Kickback Statute regulations, but can access independent foundation grant programs that provide financial assistance for prescription medications.

Uninsured or underinsured patients may qualify for patient assistance programs based on household income. QuickRx evaluates all available programs to find the best financial assistance option for your specific situation.

Call QuickRx at (917) 830-2525 or (800) 496-6111 to determine your eligibility for Hetlioz copay assistance programs.

Savings vary significantly by insurance type and program enrollment. Commercially insured patients using manufacturer copay cards may reduce their out-of-pocket costs substantially, with many eligible patients paying $0 per prescription. Annual maximum benefit limits apply to most manufacturer copay programs. Without assistance, Hetlioz can represent a significant monthly expense depending on insurance coverage and formulary tier placement.

Medicare and Medicaid patients can access foundation grants that help cover Part D deductibles, coinsurance, and copayments. Grant amounts vary by foundation and funding availability, but many patients receive assistance that significantly reduces their medication costs. The Medicare.gov website provides additional information about prescription drug coverage under Part D plans.

Uninsured patients may receive Hetlioz at significantly reduced prices or no cost through patient assistance programs administered by pharmaceutical manufacturers or independent charitable organizations. Financial assistance programs for sleep disorder medications can substantially reduce costs for qualifying patients based on household income and medical necessity.

QuickRx maximizes your savings by identifying all available programs, handling enrollment paperwork, and coordinating benefits to ensure you receive the maximum financial assistance possible. Most QuickRx patients pay $0 to $50 per month for Hetlioz with our copay assistance coordination.

Approval timelines vary by program type and application completeness. Most commercially insured patients receive manufacturer copay card approval within 24 to 48 hours of submitting a complete application with all required documentation, including valid prescription, insurance information, and patient consent forms.

Patient assistance programs and foundation grants typically require more comprehensive documentation and may take 1 to 3 weeks for processing. These programs often require proof of income, tax returns, household size verification, and detailed insurance coverage information. Processing times depend on application volume and program funding availability.

QuickRx expedites the approval process by ensuring all paperwork is complete and submitted correctly the first time, reducing delays caused by missing information or documentation errors. Our pharmacy team follows up directly with program administrators to track application status and resolve any issues quickly. We’ll keep you updated throughout the application process and can often arrange temporary medication supplies while your application is being processed.

For urgent situations, call QuickRx at (917) 830-2525 to discuss expedited enrollment options or bridge therapy solutions.

Hetlioz (tasimelteon) is used to treat Non-24-Hour Sleep-Wake Disorder (Non-24), a chronic circadian rhythm disorder where individuals are unable to synchronize their endogenous circadian pacemaker to the 24-hour light-dark cycle. According to the FDA, Hetlioz was approved in January 2014 specifically for this indication.

Non-24 is most commonly seen in individuals who are totally blind and cannot perceive light, which is the primary environmental cue that synchronizes the body’s internal clock. The National Institute of Neurological Disorders and Stroke estimates that more than 50% of completely blind individuals experience Non-24, resulting in chronic sleep disturbances, daytime sleepiness, and impaired daily functioning.

Hetlioz works as a melatonin receptor agonist, specifically targeting MT1 and MT2 melatonin receptors in the brain’s suprachiasmatic nucleus (SCN), which serves as the body’s master circadian clock. By activating these receptors at the appropriate time, tasimelteon helps to reset and maintain the body’s internal circadian clock to a 24-hour cycle, improving nighttime sleep and reducing daytime sleepiness.

For more information about Non-24-Hour Sleep-Wake Disorder, visit the MedlinePlus sleep disorders resource page or consult with a sleep medicine specialist.

Hetlioz is taken orally as a capsule. The medication should be taken once daily before bedtime, approximately at the same time each night, to maintain consistent circadian rhythm entrainment. According to the FDA-approved prescribing information, timing consistency is crucial for therapeutic effectiveness.

Hetlioz must be taken without food, meaning at least one hour before or one hour after a meal. Food can significantly affect the absorption and bioavailability of tasimelteon, potentially reducing its effectiveness. The medication should be taken with water, and capsules should be swallowed whole—do not open, crush, or chew the capsules.

The typical adult dosage is 20 mg once daily before bedtime. Your healthcare provider will prescribe the appropriate dosage based on your specific condition, response to treatment, and any other medications you may be taking. It may take several weeks to months to achieve optimal circadian rhythm entrainment, so consistent adherence to your dosing schedule is essential.

Hetlioz capsules should be stored at room temperature away from light and moisture. The medication is light-sensitive, so keep it in its original amber-colored container. For detailed administration instructions, speak with your QuickRx pharmacist at (917) 830-2525.

Common side effects of Hetlioz include headache (occurring in 17% of patients in clinical trials), urinary tract infection (7%), upper respiratory tract infection (7%), increased serum alanine aminotransferase or liver enzymes (10%), abnormal dreams (10% or less), and nightmares (10% or less). These incidence rates are based on clinical trial data submitted to the FDA during the drug approval process.

Most side effects are mild to moderate in severity and often improve with continued use as your body adjusts to the medication. Headaches typically occur during the first few weeks of treatment and usually resolve without intervention. According to MedlinePlus, drinking adequate water and maintaining consistent dosing times can help minimize headache occurrence.

Hetlioz may also cause drowsiness, dizziness, or impaired alertness, particularly when first starting treatment. Do not drive, operate heavy machinery, or perform activities requiring full alertness until you know how Hetlioz affects you. The medication’s sedative effects are intended to promote sleep and may persist into morning hours for some patients.

Contact your healthcare provider if you experience persistent or severe side effects, unusual changes in mood or behavior, signs of liver problems (yellowing of skin or eyes, dark urine, persistent nausea), or any side effects that interfere with your daily activities. The FDA MedWatch program allows patients and healthcare providers to report adverse effects associated with medications.

Hetlioz can interact with other medications because it is metabolized by liver enzymes CYP1A2 and CYP3A4. According to the FDA prescribing information, medications that affect these enzymes may alter Hetlioz levels in your body, potentially increasing side effects or reducing effectiveness.

Strong CYP3A4 inducers such as rifampin, carbamazepine, and phenytoin may significantly decrease tasimelteon blood levels, reducing its therapeutic effect. Conversely, CYP1A2 inhibitors like fluvoxamine and ciprofloxacin, or CYP3A4 inhibitors like ketoconazole and clarithromycin, may increase tasimelteon levels and enhance side effects including excessive drowsiness and CNS depression.

Hetlioz may have additive CNS depressant effects when combined with alcohol, benzodiazepines, opioids, antihistamines, or other sedating medications. The combination of multiple sedating drugs can increase the risk of excessive drowsiness, respiratory depression, falls, and other serious adverse events.

Always inform your healthcare provider and QuickRx pharmacist about all medications you are taking, including prescription drugs, over-the-counter medications, vitamins, supplements, and herbal products. This includes medications you take occasionally or as needed. Call (917) 830-2525 for a complete medication interaction review before starting Hetlioz.

Avoid alcohol and other central nervous system (CNS) depressants while taking Hetlioz, as they may increase CNS depressant effects such as excessive drowsiness, sedation, impaired coordination, and respiratory depression. The National Institute on Alcohol Abuse and Alcoholism warns that combining alcohol with sleep medications can be dangerous and potentially life-threatening.

Do not drive, operate heavy machinery, or perform activities requiring full mental alertness until you know how Hetlioz affects you. The medication is designed to promote sleep and may cause significant drowsiness, particularly during the first few weeks of treatment. According to the FDA, patients should wait at least 8 hours after taking Hetlioz before engaging in activities requiring alertness.

Avoid taking Hetlioz with food, as food can significantly affect absorption and reduce the medication’s effectiveness. Take it at least one hour before or one hour after meals. Additionally, avoid bright light exposure in the evening hours close to your Hetlioz dosing time, as this can interfere with the medication’s ability to synchronize your circadian rhythm.

Avoid grapefruit and grapefruit juice while taking Hetlioz, as grapefruit can inhibit CYP3A4 enzymes and increase tasimelteon blood levels. The MedlinePlus resource provides detailed information about food-drug interactions. If you smoke tobacco products, discuss this with your healthcare provider, as smoking can induce CYP1A2 and may affect Hetlioz levels.

If you miss a dose of Hetlioz, skip the missed dose and take your next dose at your regular scheduled time before bedtime the following night. Do not take two doses at the same time or take an extra dose to make up for a missed dose, as this can increase the risk of side effects without providing additional therapeutic benefit.

According to the FDA prescribing information, maintaining consistent dosing times is important for optimal circadian rhythm entrainment. If you miss a dose, simply resume your normal schedule the next day. Missing occasional doses may temporarily disrupt your sleep-wake cycle improvement, but the medication will continue working once you resume regular dosing.

If you miss multiple consecutive doses or frequently forget to take your medication, contact your healthcare provider or QuickRx pharmacist to discuss strategies for improving medication adherence. Setting phone alarms, using pill organizers, or linking your dose to a specific evening routine can help ensure consistent medication administration.

For more information about medication adherence strategies, the MedlinePlus resource provides helpful tips for remembering to take medications as prescribed.

It is not recommended to drink alcohol while taking Hetlioz. Alcohol is a central nervous system (CNS) depressant and may significantly increase the CNS depressant effects of tasimelteon, leading to excessive drowsiness, severe sedation, impaired motor coordination, respiratory depression, and increased fall risk.

According to the National Institute on Alcohol Abuse and Alcoholism, combining alcohol with sleep-promoting medications can be dangerous and may result in serious adverse effects including loss of consciousness, extreme confusion, and potentially life-threatening respiratory depression. The combination can also increase the risk of accidents, falls, and injuries.

Additionally, alcohol can disrupt your natural sleep architecture and interfere with Hetlioz’s ability to properly synchronize your circadian rhythm. While alcohol may initially cause drowsiness, it fragments sleep during the night and can worsen underlying sleep disorders. The Sleep Foundation provides detailed information about alcohol’s effects on sleep quality.

If you have questions about alcohol consumption or struggle with alcohol use, discuss this openly with your healthcare provider before starting Hetlioz. Your doctor can provide personalized guidance based on your complete medical history and may recommend support resources if needed.

Hetlioz is classified under Briggs’ Drugs in Pregnancy and Lactation reference, and the decision to use tasimelteon during pregnancy should be made in careful consultation with your healthcare provider, considering the potential risks to the developing fetus, the benefits of treatment to the mother, and the availability of alternative treatments.

Animal reproduction studies have shown some adverse effects, but there are limited human pregnancy data available for Hetlioz. According to the FDA, pregnant women should only use Hetlioz if the potential benefit justifies the potential risk to the fetus. The National Institute of Child Health and Human Development provides resources about medication use during pregnancy.

Regarding breastfeeding, it is not known whether tasimelteon is excreted in human breast milk. According to the manufacturer’s prescribing information, the decision to breastfeed during Hetlioz therapy should consider the risk of infant exposure to the medication, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Many medications do pass into breast milk and could affect a nursing infant.

If you are pregnant, planning to become pregnant, or breastfeeding, inform your healthcare provider immediately. Your doctor may recommend alternative treatments for Non-24-Hour Sleep-Wake Disorder that have better-established safety profiles during pregnancy and lactation. The MotherToBaby service provides free, confidential information about medications during pregnancy and breastfeeding.

The duration of Hetlioz treatment varies significantly by individual and depends on your response to therapy, ongoing management of Non-24-Hour Sleep-Wake Disorder, and whether your underlying condition (such as total blindness) remains unchanged. According to the FDA prescribing information, clinical trials have evaluated Hetlioz for extended periods, and many patients require long-term treatment to maintain proper circadian rhythm synchronization.

For most patients with Non-24, especially those who are totally blind, the underlying circadian rhythm disorder is chronic and persistent because the fundamental problem (inability to perceive light cues) remains unchanged. As a result, many patients benefit from continuous long-term Hetlioz therapy to maintain a normal sleep-wake cycle. The National Institute of Neurological Disorders and Stroke notes that circadian rhythm disorders in blind individuals typically require ongoing management.

Some patients may experience symptom improvement within days to weeks, while others may require several months of consistent treatment to achieve optimal circadian entrainment. Your healthcare provider will monitor your progress through regular follow-up appointments, sleep diary assessments, and evaluation of daytime functioning. Treatment duration decisions should be individualized based on therapeutic response and tolerability.

Never stop taking Hetlioz abruptly without consulting your healthcare provider, as discontinuation may result in return of Non-24 symptoms. If you and your doctor decide to stop treatment, a gradual tapering plan may be recommended. For more information about managing chronic sleep disorders, visit the National Sleep Foundation website.

Store Hetlioz capsules at room temperature between 68°F to 77°F (20°C to 25°C), away from moisture, heat, and direct light exposure. According to the FDA-approved prescribing information, tasimelteon is light-sensitive and should always be kept in its original amber-colored container with the cap tightly closed to protect from light degradation.

Do not store Hetlioz in bathroom medicine cabinets or near sinks, as humidity and temperature fluctuations can affect medication stability. Avoid storing the medication in your car, especially during summer months when temperatures can exceed safe storage ranges. The FDA Consumer Health Information provides general guidance on proper medication storage.

Keep Hetlioz out of reach of children and pets. Store the medication in a secure location, preferably in a locked cabinet or high shelf. If a child or pet accidentally ingests Hetlioz, immediately call the Poison Control Center at 1-800-222-1222 or seek emergency medical attention.

Do not use Hetlioz past its expiration date printed on the bottle label. Expired medication may be less effective and could potentially be harmful. Dispose of expired or unused Hetlioz properly according to local regulations or through pharmacy take-back programs. The FDA Safe Disposal of Medicines website provides detailed disposal instructions. Many pharmacies, including QuickRx, offer medication disposal services—call (917) 830-2525 to inquire about safe disposal options.

For comprehensive, evidence-based information about Hetlioz and Non-24-Hour Sleep-Wake Disorder, consult these authoritative medical resources:

Government Health Agencies:
The U.S. Food and Drug Administration (FDA) provides official prescribing information, safety alerts, and drug approval details for Hetlioz. The National Institute of Neurological Disorders and Stroke (NINDS) offers detailed information about circadian rhythm disorders and their management. MedlinePlus, provided by the National Library of Medicine, offers patient-friendly information about sleep disorders and medications.

Sleep Medicine Organizations:
The National Sleep Foundation provides educational resources about circadian rhythm disorders, sleep hygiene, and treatment options. The American Academy of Sleep Medicine offers clinical practice guidelines and patient education materials about sleep-wake disorders.

Clinical Research:
ClinicalTrials.gov lists ongoing research studies investigating tasimelteon and Non-24 disorder. The PubMed database provides access to peer-reviewed medical literature and research studies about sleep-wake disorders and melatonin receptor agonists.

Patient Support:
QuickRx Specialty Pharmacy is also available to answer questions about Hetlioz treatment, copay assistance programs, and ongoing medication management. Our specialty pharmacists can provide personalized education about your medication, side effect management, and adherence strategies. Call (917) 830-2525 or (800) 496-6111 to speak with a pharmacist specializing in sleep disorder medications.

For comprehensive, evidence-based information about Hetlioz and Non-24-Hour Sleep-Wake Disorder, consult these authoritative medical resources:

Government Health Agencies:
The U.S. Food and Drug Administration (FDA) provides official prescribing information, safety alerts, and drug approval details for Hetlioz. The National Institute of Neurological Disorders and Stroke (NINDS) offers detailed information about circadian rhythm disorders and their management. MedlinePlus, provided by the National Library of Medicine, offers patient-friendly information about sleep disorders and medications.

Sleep Medicine Organizations:
The National Sleep Foundation provides educational resources about circadian rhythm disorders, sleep hygiene, and treatment options. The American Academy of Sleep Medicine offers clinical practice guidelines and patient education materials about sleep-wake disorders.

Clinical Research:
ClinicalTrials.gov lists ongoing research studies investigating tasimelteon and Non-24 disorder. The PubMed database provides access to peer-reviewed medical literature and research studies about sleep-wake disorders and melatonin receptor agonists.

Patient Support:
QuickRx Specialty Pharmacy is also available to answer questions about Hetlioz treatment, copay assistance programs, and ongoing medication management. Our specialty pharmacists can provide personalized education about your medication, side effect management, and adherence strategies. Call (917) 830-2525 or (800) 496-6111 to speak with a pharmacist specializing in sleep disorder medications.